This is the "new" hook. For the first time, a MIRD model accounts for T-cell infiltration and hypoxic zones. Tumors with high PD-L1 expression, it turns out, have different radiation absorption kinetics. The "new" algorithm recalibrates dosing based on a fresh biopsy's RNA-seq data, effectively merging immuno-oncology with radiodosimetry.
Before understanding the "new," we must respect the "old." mird237 new
The MIRD system—developed by the Society of Nuclear Medicine and Molecular Imaging (SNMMI)—has been the gold standard for calculating absorbed doses in targeted radionuclide therapy (TRT). Drugs like Lutathera (for neuroendocrine tumors) and Pluvicto (for prostate cancer) rely on MIRD-based dosimetry to ensure that radioactive isotopes kill cancer cells without obliterating bone marrow or kidneys. This is the "new" hook
For decades, the "MIRD" pamphlets (1 through 23) provided the mathematical skeletons. But as personalized medicine advanced, static models began to crack. Enter the need for "MIRD237" – a theoretical next-generation schema that incorporates real-time patient-specific variables. The "new" algorithm recalibrates dosing based on a
As of May 2026, the "MIRD237 new" protocol is available through:
